Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial - PubMed (original) (raw)

Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial

Candida J Rebello et al. BBA Clin. 2015.

Abstract

Background: Impaired brain glucose metabolism appears to be a potential pathogenic feature of mild cognitive impairment (MCI). This study examined the potential for increasing circulating ketone bodies through medium chain triglyceride (MCT) supplementation, as a means to beneficially modulate brain homeostasis in subjects with MCI.

Methods: Six participants with MCI were enrolled in a randomized placebo-controlled trial. Participants received 56 g/day of either medium chain triglycerides (MCTs) or placebo for 24 weeks. Serum β-hydroxybutyrate concentrations, apolipoprotein-E4 status, and cognitive assessments were carried out. Due to the small number of participants only the raw scores were examined.

Results: Intake of MCT oil increased serum ketone bodies and improved memory, while intake of placebo did not show improvement in any of the cognitive measures tested.

Conclusions: Consumption of 56 g/day of MCTs for 24 weeks increases serum ketone concentrations and appears to be a candidate for larger randomized control trials in the future that quantify the modulation of cognitive function through supplementation with ketone precursors, in patients with MCI.

Keywords: Alzheimer's disease; Ketone bodies; Medium chain triglycerides; Memory; Mild cognitive impairment.

PubMed Disclaimer

References

    1. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013;108:21–43. - PubMed
    1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387–403. - PubMed
    1. Cunnane S., Nugent S., Roy M., Courchesne-Loyer A., Croteau E., Tremblay S., Castellano A., Pifferi F., Bocti C., Paquet N., Begdouri H., Bentourkia M., Turcotte E., Allard M., Barberger-Gateau P., Fulop T., Rapoport S.I. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 2011;27:3–20. - PMC - PubMed
    1. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta. 1842;2014:1219–1231. - PMC - PubMed
    1. Reger M.A., Henderson S.T., Hale C., Cholerton B., Baker L.D., Watson G.S., Hyde K., Chapman D., Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging. 2004;25:311–314. - PubMed

LinkOut - more resources